Literature DB >> 17120157

Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.

Zhang Xiangsong1, Chen Weian.   

Abstract

UNLABELLED: Differentiation of posttherapy radiation necrosis from recurrent brain tumor remains a challenging diagnostic problem. The combination of the imaging modalities on the basis of different physiologic mechanisms could improve diagnostic accuracy. The present study assessed the role of (13)N-NH(3) PET in differentiating recurrent cerebral astrocytoma from radiation necrosis.
METHODS: Seven patients, who were previously treated with conventional external-beam radiation therapy after surgical resection for cerebral astrocytomas, and showed the enhancing brain lesions on T1-weighted gadiolinium-enhanced MR studies performed in 6 months or above after the radiotherapies, were examined prospectively with (13)N-NH(3) and FDG PET. Five lesions with tumor recurrence and two with radiation necrosis were histologically verified by either surgical resection or stereotactic biopsy. One lesion of radiation necrosis was confirmed clinicoradiologically.
RESULTS: In all eight lesions the (13)N-NH(3) PET scans were concordant with the final diagnosis (100%, 8/8). The lesions with recurrent tumor showed moderately to markedly increased (13)N-NH(3) uptake (grade = 4-5). The lesions with radiation necrosis showed absent or less (13)N-NH(3) uptake than surrounding area (grade = 1-2). The FDG PET scans were concordant with the final diagnosis in six of eight lesions (75%, 6/8), and there were one false-negative result and one false-positive result. The diagnostic result of (13)N-NH(3) PET was discordant with FDG PET in two lesions. One lesion with gliosis and radiation necrosis showed slightly increased FDG uptake (grade = 4), but less (13)N-NH(3) uptake (grade = 2). The other lesion with anaplastic astrocytoma showed moderately increased (13)N-NH(3) uptake (grade = 4), but slightly less FDG uptake than surrounding area (grade = 2).
CONCLUSIONS: The recurrent astrocytomas showed increased (13)N-NH(3) uptake, and the radiation necrosis showed absent or less (13)N-NH(3) uptake, and (13)N-NH(3) seem superior to (18)F-FDG for this purpose, suggesting that (13)N-NH(3) is a promising tracer for separating radiation necrosis from astrocytoma recurrence. However, the patient population in this study was small. Thus, the further studies are needed to settle this issue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120157     DOI: 10.1007/s11060-006-9286-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  17 in total

1.  Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?

Authors:  P E Ricci; J P Karis; J E Heiserman; E K Fram; A N Bice; B P Drayer
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

2.  The metabolic fate of 13N-labeled ammonia in rat brain.

Authors:  A J Cooper; J M McDonald; A S Gelbard; R F Gledhill; T E Duffy
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

3.  New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose.

Authors:  C K Kim; J B Alavi; A Alavi; M Reivich
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

4.  Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.

Authors:  T J Janus; E E Kim; R Tilbury; J M Bruner; W K Yung
Journal:  Ann Neurol       Date:  1993-05       Impact factor: 10.422

5.  The role of glutamine synthetase in the diagnosis of cerebral tumours.

Authors:  G J Pilkington; P L Lantos
Journal:  Neuropathol Appl Neurobiol       Date:  1982 May-Jun       Impact factor: 8.090

6.  Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing.

Authors:  L Fucci; C N Oliver; M J Coon; E R Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  [Immunohistochemical study of glutamine synthetase expression in normal human brain and intracranial tumors].

Authors:  J Akimoto
Journal:  No To Shinkei       Date:  1993-04

8.  Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography.

Authors:  P A Carvalho; R B Schwartz; E Alexander; B M Garada; R E Zimmerman; J S Loeffler; B L Holman
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

9.  Cerebral extraction of N-13 ammonia: its dependence on cerebral blood flow and capillary permeability -- surface area product.

Authors:  M E Phelps; S C Huang; E J Hoffman; C Selin; D E Kuhl
Journal:  Stroke       Date:  1981 Sep-Oct       Impact factor: 7.914

10.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.

Authors:  T Sugahara; Y Korogi; S Tomiguchi; Y Shigematsu; I Ikushima; T Kira; L Liang; Y Ushio; M Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

View more
  19 in total

1.  Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.

Authors:  Bangkim Chandra Khangembam; Sellam Karunanithi; Punit Sharma; Sudhir Suman Kc; Rajeev Kumar; Pramod Kumar Julka; Rakesh Kumar; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2014-07-03       Impact factor: 2.804

Review 2.  13N-NH3 PET/CT in oncological disease.

Authors:  Domenico Albano; Raffaele Giubbini; Francesco Bertagna
Journal:  Jpn J Radiol       Date:  2019-10-10       Impact factor: 2.374

Review 3.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

4.  Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.

Authors:  Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman
Journal:  Clin Nucl Med       Date:  2012-09       Impact factor: 7.794

Review 5.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Authors:  Ashish H Shah; Brian Snelling; Amade Bregy; Payal R Patel; Danoushka Tememe; Rita Bhatia; Evelyn Sklar; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2013-01-24       Impact factor: 4.130

6.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

Review 7.  Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.

Authors:  Jennifer L Clarke; Susan Chang
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

8.  Current concepts on imaging in radiotherapy.

Authors:  Michela Lecchi; Piero Fossati; Federica Elisei; Roberto Orecchia; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-31       Impact factor: 9.236

Review 9.  Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

Authors:  Natalie R Boonzaier; Sara G M Piccirillo; Colin Watts; Stephen J Price
Journal:  CNS Oncol       Date:  2015-10-26

10.  Identify glioma recurrence and treatment effects with triple-tracer PET/CT.

Authors:  Cong Li; Chang Yi; Yingshen Chen; Shaoyan Xi; Chengcheng Guo; Qunying Yang; Jian Wang; Ke Sai; Ji Zhang; Chao Ke; Fanfan Chen; Yanchun Lv; Xiangsong Zhang; Zhongping Chen
Journal:  BMC Med Imaging       Date:  2021-05-31       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.